Recent advances in the first-line management of advanced RCC (VIRTUAL)

Sponsored by EISAI EUROPE LTD
01 July 2022, 16:15 - 17:15 CEST

Looking towards the future: considerations for treatment strategies across the spectrum of advanced prostate cancer (HYBRID)

Sponsored by JANSSEN EMEA
01 July 2022, 16:15 - 17:45 CEST

Advances in the management of acute and recurrent UTIs caused by resistant pathogens – what’s next? (HYBRID)

Sponsored by GLAXOSMITHKLINE
01 July 2022, 16:15 - 17:45 CEST

Coloplast TFL Drive: a new way to drive settings (ONSITE)

Sponsored by COLOPLAST
01 July 2022, 16:45 - 17:45 CEST

Evolving Concepts in Metastatic Prostate Cancer (VIRTUAL)

Sponsored by PFIZER ONCOLOGY
01 July 2022, 19:30 - 20:30 CEST

Navigating the real-world use of PARP inhibitors in BRCAm mCRPC: a practical discussion (HYBRID)

Sponsored by ASTRAZENECA
02 July 2022, 18:30 - 20:00 CEST

Immuno-Oncology for Muscle-Invasive Urothelial Carcinoma: Exploring Opportunities for Perioperative Use (HYBRID)

Sponsored by BRISTOL-MYERS SQUIBB
02 July 2022, 18:30 - 20:00 CEST

Practical considerations for early-stage bladder cancer: case-based discussions for managing patients with NMIBC and MIBC (HYBRID)

Sponsored by JANSSEN EMEA
02 July 2022, 18:30 - 20:00 CEST

Evidence-based approaches for optimising metastatic hormone-sensitive prostate cancer (mHSPC) patient care: treatment intensification to improve survival (HYBRID)

Sponsored by ASTELLAS PHARMA EUROPE LTD.
03 July 2022, 17:45 - 19:15 CEST

Improvements in prostate cancer management: Focus on imaging and treatment (HYBRID)

Sponsored by TELIX PHARMACEUTICALS
03 July 2022, 17:45 - 19:15 CEST

Advancing patient care in the evolving prostate cancer treatment landscape (HYBRID)

Sponsored by BAYER AG
03 July 2022, 17:45 - 19:15 CEST

Expert Guidance in Non-Muscle Invasive Bladder Cancer: Applying the Latest Recommendations to Clinical Practice (ONSITE)

Sponsored by MEDAC GMBH
03 July 2022, 17:45 - 19:15 CEST

  • © 2022 European Association of Urology
  • Disclaimer